SCHEMBL6049285

SCHEMBL6049285

COc1cc(OCC(C)O)ccc1O[Si](C)(C)C(C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.42
LMNA P02545 1/20 0.40
HIF1A Q16665 1/20 0.37
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA7 P43166 1/20 0.37
CA9 Q16790 1/20 0.37
CA14 Q9ULX7 1/20 0.37
KMT2A Q03164 1/20 0.36
SCN1A P35498 1/20 0.36
SCN2A Q99250 1/20 0.36
SCN3A Q9NY46 1/20 0.36
KDM4E B2RXH2 1/20 0.35
ADRA2A P08913 2/20 0.35
ADRA1A P35348 2/20 0.35
TSHR P16473 1/20 0.34
MAPK1 P28482 1/20 0.34
CYP2D6 P10635 1/20 0.34
ADRB2 P07550 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20719974 0.83 CA12 (0.53) LMNAHIF1ACA12CA1CA2
SCHEMBL12120169 0.81 DRD2 (0.43) DRD2CA12CA1CA2CA7
SCHEMBL13640332 0.80 CA12 (0.59) DRD2LMNACA12CA1CA2
SCHEMBL6049292 0.75 ALDH1A1 (0.49) DRD2LMNAHIF1ACA12CA1
SCHEMBL15004196 0.74 DRD2 (0.47) DRD2HIF1AKMT2ATSHR
SCHEMBL6049300 0.74 DRD2 (0.47) DRD2LMNAKMT2AKDM4ETSHR
SCHEMBL10631858 0.73 ALDH1A1 (0.56) LMNACA1CA2KMT2AADRA2A
SCHEMBL14980756 0.73 ALDH1A1 (0.56) LMNACA1CA2KMT2AADRA2A
SCHEMBL6049222 0.72 MAOB (0.48) DRD2KMT2AKDM4EMAPK1
SCHEMBL16535794 0.72 IDO1 (0.45) DRD2CA12CA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060264480-A1 Novel thiocarbamic acid derivatives and the pharmaceutical compositions containing the same SUH YOUNG G 2006-11-23 US disclosed
EP-1311477-A4 NOVEL THIOCARBAMIC ACID DERIVATIVES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME PACIFIC CORP (KR) 2005-01-12 EP disclosed
US-20030203944-A1 Novel thiocarbamic acid derivatives and the pharmaceutical compositions containing the same PACIFIC CORPORATION (KR) 2003-10-30 US disclosed
EP-1311477-A1 NOVEL THIOCARBAMIC ACID DERIVATIVES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME PACIFIC CORPORATION (KR) 2003-05-21 EP disclosed
WO-2002016317-A1 NOVEL THIOCARBAMIC ACID DERIVATIVES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME PACIFIC CORPORATION (KR) 2002-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264480-A1 Novel thiocarbamic acid derivatives and the pharmaceutical compositions containing the same TRPV1, TRPA1, TRPV5 DRD2 1369/4885LMNA 4260/4885HIF1A 1505/4885
US-20030203944-A1 Novel thiocarbamic acid derivatives and the pharmaceutical compositions containing the same TRPV1, TRPA1, TRPV5 DRD2 1369/4885LMNA 4260/4885HIF1A 1505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.